Published in ASN Neuro on April 07, 2011
Effects of dimethyl fumarate on neuroprotection and immunomodulation. J Neuroinflammation (2012) 1.47
Emerging roles of Nrf2 and phase II antioxidant enzymes in neuroprotection. Prog Neurobiol (2012) 1.41
The Nrf2-ARE pathway: a valuable therapeutic target for the treatment of neurodegenerative diseases. Recent Pat CNS Drug Discov (2012) 1.13
Dimethylfumarate attenuates renal fibrosis via NF-E2-related factor 2-mediated inhibition of transforming growth factor-β/Smad signaling. PLoS One (2012) 1.01
Dimethyl fumarate and monoethyl fumarate exhibit differential effects on KEAP1, NRF2 activation, and glutathione depletion in vitro. PLoS One (2015) 0.94
Regulation of dimethyl-fumarate toxicity by proteasome inhibitors. Cancer Biol Ther (2014) 0.88
Protein carbonylation and aggregation precede neuronal apoptosis induced by partial glutathione depletion. ASN Neuro (2012) 0.88
Anti-inflammatory dimethylfumarate: a potential new therapy for asthma? Mediators Inflamm (2013) 0.86
Carbon monoxide and the CNS: challenges and achievements. Br J Pharmacol (2014) 0.86
Dimethyl Fumarate Protects Neural Stem/Progenitor Cells and Neurons from Oxidative Damage through Nrf2-ERK1/2 MAPK Pathway. Int J Mol Sci (2015) 0.86
Molecular pharmacodynamics of new oral drugs used in the treatment of multiple sclerosis. Drug Des Devel Ther (2014) 0.85
Dimethyl fumarate and the oleanane triterpenoids, CDDO-imidazolide and CDDO-methyl ester, both activate the Nrf2 pathway but have opposite effects in the A/J model of lung carcinogenesis. Carcinogenesis (2015) 0.84
Dimethyl fumarate modulation of immune and antioxidant responses: application to HIV therapy. Crit Rev Immunol (2013) 0.83
Fumaric acid esters stimulate astrocytic VEGF expression through HIF-1α and Nrf2. PLoS One (2013) 0.82
Positively Charged Oligo[Poly(Ethylene Glycol) Fumarate] Scaffold Implantation Results in a Permissive Lesion Environment after Spinal Cord Injury in Rat. Tissue Eng Part A (2015) 0.81
Beneficial actions of the anti-inflammatory dimethyl fumarate in glioblastomas. Surg Neurol Int (2013) 0.81
What do effective treatments for multiple sclerosis tell us about the molecular mechanisms involved in pathogenesis? Int J Mol Sci (2012) 0.81
Multiple sclerosis: molecular mechanisms and therapeutic opportunities. Antioxid Redox Signal (2013) 0.80
Fumaric acid esters can block pro-inflammatory actions of human CRP and ameliorate metabolic disturbances in transgenic spontaneously hypertensive rats. PLoS One (2014) 0.79
Monomethyl fumarate augments NK cell lysis of tumor cells through degranulation and the upregulation of NKp46 and CD107a. Cell Mol Immunol (2014) 0.79
Distinct Nrf2 Signaling Mechanisms of Fumaric Acid Esters and Their Role in Neuroprotection against 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine-Induced Experimental Parkinson's-Like Disease. J Neurosci (2016) 0.79
Chemical proteomic map of dimethyl fumarate-sensitive cysteines in primary human T cells. Sci Signal (2016) 0.78
Dimethyl fumarate modulates antioxidant and lipid metabolism in oligodendrocytes. Redox Biol (2015) 0.78
Nuclear Factor-Erythroid-2-Related Factor 2 in Aging and Lung Fibrosis. Am J Pathol (2016) 0.77
Utilization of Dimethyl Fumarate and Related Molecules for Treatment of Multiple Sclerosis, Cancer, and Other Diseases. Front Immunol (2016) 0.77
Nrf2-dysregulation correlates with reduced synthesis and low glutathione levels in experimental autoimmune encephalomyelitis. J Neurochem (2016) 0.77
Dimethyl fumarate treatment of relapsing-remitting multiple sclerosis influences B-cell subsets. Neurol Neuroimmunol Neuroinflamm (2016) 0.76
Promoting return of function in multiple sclerosis: An integrated approach. Mult Scler Relat Disord (2013) 0.76
Dimethyl Fumarate Induces Glutathione Recycling by Upregulation of Glutathione Reductase. Oxid Med Cell Longev (2017) 0.76
Lipopolysaccharide Binding Protein and Oxidative Stress in a Multiple Sclerosis Model. Neurotherapeutics (2016) 0.75
Benfotiamine upregulates antioxidative system in activated BV-2 microglia cells. Front Cell Neurosci (2015) 0.75
NF-κB Pathways in the Pathogenesis of Multiple Sclerosis and the Therapeutic Implications. Front Mol Neurosci (2016) 0.75
Sulforaphane Inhibits HIV Infection of Macrophages through Nrf2. PLoS Pathog (2016) 0.75
Dimethyl fumarate in the management of multiple sclerosis: appropriate patient selection and special considerations. Ther Clin Risk Manag (2016) 0.75
Analysis of nitrate, nitrite, and [15N]nitrate in biological fluids. Anal Biochem (1982) 27.26
Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study. Lancet (2008) 3.68
Astrocytes induce hemeoxygenase-1 expression in microglia: a feasible mechanism for preventing excessive brain inflammation. J Neurosci (2006) 2.25
The role of nitric oxide in multiple sclerosis. Lancet Neurol (2002) 2.00
Fumaric acid esters are effective in chronic experimental autoimmune encephalomyelitis and suppress macrophage infiltration. Clin Exp Immunol (2006) 1.62
Review of molecular mechanisms involved in the activation of the Nrf2-ARE signaling pathway by chemopreventive agents. Methods Mol Biol (2010) 1.46
Dimethylfumarate inhibits microglial and astrocytic inflammation by suppressing the synthesis of nitric oxide, IL-1beta, TNF-alpha and IL-6 in an in-vitro model of brain inflammation. J Neuroinflammation (2010) 1.41
Dimethylfumarate inhibits TNF-induced nuclear entry of NF-kappa B/p65 in human endothelial cells. J Immunol (2002) 1.39
Dimethylfumarate induces immunosuppression via glutathione depletion and subsequent induction of heme oxygenase 1. J Invest Dermatol (2007) 1.32
Dimethylfumarate for psoriasis: more than a dietary curiosity. Trends Mol Med (2005) 1.31
Reactive nitrogen intermediates in human neuropathology: an overview. Dev Neurosci (1994) 1.27
Reactivity of dimethyl fumarate and methylhydrogen fumarate towards glutathione and N-acetyl-L-cysteine--preparation of S-substituted thiosuccinic acid esters. Bioorg Med Chem (2006) 1.26
Detoxication enzyme inducers modify cytokine production in rat mixed glial cells. J Neuroimmunol (2005) 1.20
Inhibition of nitric oxide synthase for treatment of experimental autoimmune encephalomyelitis. J Immunol (1997) 1.19
The antipsoriatic drug dimethylfumarate strongly suppresses chemokine production in human keratinocytes and peripheral blood mononuclear cells. Br J Dermatol (2001) 1.08
Acetylcarnitine induces heme oxygenase in rat astrocytes and protects against oxidative stress: involvement of the transcription factor Nrf2. J Neurosci Res (2005) 1.08
Dimethylfumarate inhibits NF-{kappa}B function at multiple levels to limit airway smooth muscle cell cytokine secretion. Am J Physiol Lung Cell Mol Physiol (2009) 1.07
Induction of nitric oxide synthase in rat C6 glioma cells. J Neurochem (1994) 1.05
Induction of glutathione transferases and NAD(P)H:quinone reductase by fumaric acid derivatives in rodent cells and tissues. Cancer Res (1990) 1.04
Dimethylfumarate is an inhibitor of cytokine-induced nuclear translocation of NF-kappa B1, but not RelA in normal human dermal fibroblast cells. J Invest Dermatol (2001) 1.04
Fumaric acid diesters deprive cultured primary astrocytes rapidly of glutathione. Neurochem Int (2010) 1.03
Effect of dietary inducer dimethylfumarate on glutathione in cultured human retinal pigment epithelial cells. Invest Ophthalmol Vis Sci (1999) 1.01
Astrocytes and microglia express inducible nitric oxide synthase in mice with experimental allergic encephalomyelitis. J Neuroimmunol (1997) 1.00
Hypoxia/reoxygenation differentially modulates NF-kappaB activation and iNOS expression in astrocytes and microglia. Antioxid Redox Signal (2006) 0.96
A 27-bp region of the inducible nitric oxide synthase promoter regulates expression in glial cells. J Neurochem (2001) 0.92
Inducible nitric oxide synthase in Theiler's murine encephalomyelitis virus infection. J Virol (1997) 0.91
Dimethyl fumarate, a small molecule drug for psoriasis, inhibits Nuclear Factor-kappaB and reduces myocardial infarct size in rats. Eur J Pharmacol (2008) 0.89
Prior induction of heme oxygenase-1 with glutathione depletor ameliorates the renal ischemia and reperfusion injury in the rat. FEBS Lett (2002) 0.88
Dimethylfumarate inhibits nuclear binding of nuclear factor kappaB but not of nuclear factor of activated T cells and CCAAT/enhancer binding protein beta in activated human T cells. Br J Dermatol (2007) 0.86
Beneficial effects of dimethyl fumarate on experimental autoimmune myocarditis. Arch Med Res (2008) 0.85
Toxic effects of acute glutathione depletion by buthionine sulfoximine and dimethylfumarate on murine mammary carcinoma cells. Radiat Res (1988) 0.83
Nitric oxide synthase expression and enzymatic activity in multiple sclerosis. Acta Neurol Scand (2004) 0.81
Evidence of covalent interaction of fumaric acid esters with sulfhydryl groups in peptides. J Mass Spectrom (2005) 0.79
Lipid emulsion infusion rescues dogs from bupivacaine-induced cardiac toxicity. Reg Anesth Pain Med (2003) 3.87
Lipid emulsion is superior to vasopressin in a rodent model of resuscitation from toxin-induced cardiac arrest. Crit Care Med (2009) 3.56
Rapid cardiotonic effects of lipid emulsion infusion*. Crit Care Med (2013) 2.76
Lipid infusion accelerates removal of bupivacaine and recovery from bupivacaine toxicity in the isolated rat heart. Reg Anesth Pain Med (2006) 2.74
Lipid infusion resuscitation for local anesthetic toxicity: proof of clinical efficacy. Anesthesiology (2006) 2.21
Epinephrine impairs lipid resuscitation from bupivacaine overdose: a threshold effect. Anesthesiology (2009) 2.11
Peroxisome proliferator-activated receptor-gamma agonists prevent experimental autoimmune encephalomyelitis. Ann Neurol (2002) 1.86
Peroxisome proliferator-activated receptor-gamma agonists induce neuroprotection following transient focal ischemia in normotensive, normoglycemic as well as hypertensive and type-2 diabetic rodents. J Neurochem (2007) 1.61
ELL-associated factor 2 (EAF2), a functional homolog of EAF1 with alternative ELL binding properties. Blood (2002) 1.54
Resuscitation with lipid emulsion: dose-dependent recovery from cardiac pharmacotoxicity requires a cardiotonic effect. Anesthesiology (2014) 1.53
Locus coeruleus damage and noradrenaline reductions in multiple sclerosis and experimental autoimmune encephalomyelitis. Brain (2011) 1.50
Noradrenergic depletion potentiates beta -amyloid-induced cortical inflammation: implications for Alzheimer's disease. J Neurosci (2002) 1.46
Intravenous lipid emulsion in clinical toxicology. Scand J Trauma Resusc Emerg Med (2010) 1.39
Protective effects of a peroxisome proliferator-activated receptor-beta/delta agonist in experimental autoimmune encephalomyelitis. J Neuroimmunol (2005) 1.29
Resuscitation with lipid versus epinephrine in a rat model of bupivacaine overdose. Anesthesiology (2008) 1.28
Proinflammatory-activated trigeminal satellite cells promote neuronal sensitization: relevance for migraine pathology. Mol Pain (2009) 1.24
Astrocyte-derived MCP-1 mediates neuroprotective effects of noradrenaline. J Neurosci (2009) 1.22
Erythropoietin exerts anti-apoptotic effects on rat microglial cells in vitro. Eur J Neurosci (2002) 1.20
A novel fluorescent probe that is brain permeable and selectively binds to myelin. J Histochem Cytochem (2006) 1.19
Peroxisome proliferator-activated receptor gamma thiazolidinedione agonists increase glucose metabolism in astrocytes. J Biol Chem (2002) 1.18
Involvement of mTOR kinase in cytokine-dependent microglial activation and cell proliferation. Biochem Pharmacol (2009) 1.17
Noradrenergic regulation of inflammatory gene expression in brain. Neurochem Int (2002) 1.17
Inhibition of in vivo glioma growth and invasion by peroxisome proliferator-activated receptor gamma agonist treatment. Mol Pharmacol (2006) 1.14
Relationship of body mass index with main limb fragility fractures in postmenopausal women. J Bone Miner Metab (2009) 1.13
P2x7 deficiency suppresses development of experimental autoimmune encephalomyelitis. J Neuroinflammation (2008) 1.12
Noradrenaline deficiency in brain increases beta-amyloid plaque burden in an animal model of Alzheimer's disease. Neurobiol Aging (2006) 1.11
The clinical course of experimental autoimmune encephalomyelitis is associated with a profound and sustained transcriptional activation of the genes encoding toll-like receptor 2 and CD14 in the mouse CNS. Brain Pathol (2002) 1.10
Identification of complement 5a-like receptor (C5L2) from astrocytes: characterization of anti-inflammatory properties. J Neurochem (2005) 1.10
Lipid, not propofol, treats bupivacaine overdose. Anesth Analg (2004) 1.06
The mTOR kinase inhibitor rapamycin decreases iNOS mRNA stability in astrocytes. J Neuroinflammation (2011) 1.05
The heat-shock protein 90 inhibitor 17-allylamino-17-demethoxygeldanamycin suppresses glial inflammatory responses and ameliorates experimental autoimmune encephalomyelitis. J Neurochem (2006) 1.04
Anti-inflammatory and antiproliferative actions of PPAR-gamma agonists on T lymphocytes derived from MS patients. J Leukoc Biol (2003) 1.04
Inhibition of microglial inflammatory responses by norepinephrine: effects on nitric oxide and interleukin-1beta production. J Neuroinflammation (2004) 1.03
The noradrenaline precursor L-DOPS reduces pathology in a mouse model of Alzheimer's disease. Neurobiol Aging (2011) 1.03
mTOR kinase, a key player in the regulation of glial functions: relevance for the therapy of multiple sclerosis. Glia (2012) 1.02
Effect of pioglitazone treatment in a patient with secondary multiple sclerosis. J Neuroinflammation (2004) 1.00
A PPARdelta agonist reduces amyloid burden and brain inflammation in a transgenic mouse model of Alzheimer's disease. Curr Alzheimer Res (2009) 0.99
Neuroprotective actions of noradrenaline: effects on glutathione synthesis and activation of peroxisome proliferator activated receptor delta. J Neurochem (2007) 0.98
Isolation of Bartonella vinsonii subsp. berkhoffii genotype II from a boy with epithelioid hemangioendothelioma and a dog with hemangiopericytoma. J Clin Microbiol (2009) 0.97
Effect of pioglitazone treatment on behavioral symptoms in autistic children. J Neuroinflammation (2007) 0.95
Bartonella species bacteremia in two patients with epithelioid hemangioendothelioma. J Clin Microbiol (2011) 0.95
Norepinephrine protects cortical neurons against microglial-induced cell death. J Neurosci Res (2005) 0.94
Update on the use of lipid emulsions in local anesthetic systemic toxicity: a focus on differential efficacy and lipid emulsion as part of advanced cardiac life support. Int Anesthesiol Clin (2011) 0.94
Novel sensitive, specific and rapid pharmacogenomic test for the prediction of abacavir hypersensitivity reaction: HLA-B*57:01 detection by real-time PCR. Pharmacogenomics (2011) 0.94
Increasing CNS noradrenaline reduces EAE severity. J Neuroimmune Pharmacol (2009) 0.93
The role of the glia limitans in ADP-induced pial arteriolar relaxation in intact and ovariectomized female rats. Am J Physiol Heart Circ Physiol (2004) 0.92
Effects of lovastatin and pravastatin on amyloid processing and inflammatory response in TgCRND8 brain. Neurochem Res (2004) 0.92
Partitioning effect in lipid resuscitation: further evidence for the lipid sink. Crit Care Med (2010) 0.92
Intravenous lipid emulsion for the treatment of drug toxicity. J Intensive Care Med (2012) 0.91
Angiotensin I-converting enzyme Gln1069Arg mutation impairs trafficking to the cell surface resulting in selective denaturation of the C-domain. PLoS One (2010) 0.91
Epinephrine induces rapid deterioration in pulmonary oxygen exchange in intact, anesthetized rats: a flow and pulmonary capillary pressure-dependent phenomenon. Anesthesiology (2012) 0.91
A pilot test of pioglitazone as an add-on in patients with relapsing remitting multiple sclerosis. J Neuroimmunol (2009) 0.91
Modulation of inducible nitric oxide synthase expression by sumoylation. J Neuroinflammation (2009) 0.91
Noradrenergic depletion increases inflammatory responses in brain: effects on IkappaB and HSP70 expression. J Neurochem (2003) 0.90
Estrogen inhibits NF kappa B-dependent inflammation in brain endothelium without interfering with I kappa B degradation. Neuroreport (2002) 0.89
Intrinsic regulation of brain inflammatory responses. Cell Mol Neurobiol (2003) 0.88
Expression of the glioma-associated oncogene homolog 1 (gli1) in advanced serous ovarian cancer is associated with unfavorable overall survival. PLoS One (2013) 0.88
LIPAEMIC report: results of clinical use of intravenous lipid emulsion in drug toxicity reported to an online lipid registry. J Med Toxicol (2014) 0.87
Investigation of immunosuppressive mechanisms in a mouse glioma model. J Neurooncol (2009) 0.87
15-deoxy-Delta12,14-prostaglandin J2 (15d-PGJ2) and ciglitazone modulate Staphylococcus aureus-dependent astrocyte activation primarily through a PPAR-gamma-independent pathway. J Neurochem (2006) 0.86
Local anesthetic toxicity and lipid resuscitation in pregnancy. Curr Opin Anaesthesiol (2011) 0.86
Propentofylline attenuates tau hyperphosphorylation in Alzheimer's Swedish mutant model Tg2576. Neuropharmacology (2005) 0.86
Norepinephrine increases I kappa B alpha expression in astrocytes. J Biol Chem (2002) 0.85
Modulatory effects of the CCR5 antagonist maraviroc on microglial pro-inflammatory activation elicited by gp120. J Neurochem (2011) 0.85
Effects of noradrenaline on neuronal NOS2 expression and viability. Antioxid Redox Signal (2006) 0.84
The mTOR kinase inhibitors polarize glioma-activated microglia to express a M1 phenotype. J Neuroinflammation (2014) 0.84
Effects of pioglitazone on diffusion tensor imaging indices in multiple sclerosis patients. Neurosci Lett (2010) 0.84
Antinociceptive activity of buprenorphine and lumiracoxib in the rat orofacial formalin test: a combination analysis study. Eur J Pharmacol (2009) 0.83